Microsoft word - document2

Group 1: Carcinogenic to Humans (108) (16 January 2009) Agents and Group of Agents 4-Aminobiphenyl [92-67-1] (Vol. 1, Suppl. 7, Vol. 99; in preparation) Aristolochic acid (Vol. 82, Vol. 100A; in preparation) (NB: Overall evaluation upgraded from 2A to 1 based on mechanistic and other relevant data) Arsenic [7440-38-2] and arsenic compounds (Vol. 23, Suppl. 7; 1987) (NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group) Asbestos [1332-21-4] (Vol. 14, Suppl. 7; 1987) Azathioprine [446-86-6] (Vol. 26, Suppl. 7, Vol. 100A; in preparation) Benzene [71-43-2] (Vol. 29, Suppl. 7; 1987) Benzidine [92-87-5] (Vol. 29, Suppl. 7, Vol. 99; in preparation) Benzo[a]pyrene [50-32-8] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 2B to 1 based on mechanistic and other relevant data) Beryllium [7440-41-7] and beryllium compounds (Vol. 58; 1993) N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine) [494-03-1] (Vol. 4, Suppl. 7, Vol. 100A; in preparation) Bis(chloromethyl)ether [542-88-1] and chloromethyl methyl ether [107-30-2] (technical-grade) (Vol. 4, Suppl. 7; 1987) 1,3-Butadiene [106-99-0] (Vol. 71, Vol. 97; 2008) 1,4-Butanediol dimethanesulfonate (Busulphan; Myleran) [55-98-1] (Vol. 4, Suppl. 7, Vol. 100A; in preparation) Cadmium [7440-43-9] and cadmium compounds (Vol. 58; 1993) Chlorambucil [305-03-3] (Vol. 26, Suppl. 7, Vol. 100A; in preparation) 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU; Semustine) [13909-09-6] (Suppl. 7, Vol. 100A; in preparation) Chromium[VI] (Vol. 49; 1990) Cyclophosphamide [50-18-0] [6055-19-2] (Vol. 26, Suppl. 7, Vol. 100A; in preparation) Cyclosporine [79217-60-0] (Vol. 50, Vol. 100A; in preparation) Diethylstilboestrol [56-53-1] (Vol. 21, Suppl. 7, Vol. 100A; in preparation) Dyes metabolized to benzidine (Vol. 99; in preparation) (NB: Overall evaluation upgraded to Group 1 based on mechanistic and other relevant data) Epstein-Barr virus (Vol. 70; 1997) Erionite [66733-21-9] (Vol. 42, Suppl. 7; 1987) Estrogen-progestogen menopausal therapy (combined) (Vol. 72, Vol. 91, Vol. 100A; in preparation) Estrogen-progestogen oral contraceptives (combined) (Vol. 72, Vol. 91, Vol. 100A; in preparation) (NB: There is also convincing evidence in humans that these agents confer a protective effect against cancer in the endometrium and ovary) Estrogens, nonsteroidal (Suppl. 7, Vol. 100A; in preparation) (NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group) Estrogens, steroidal (Suppl. 7, Vol. 100A; in preparation) (NB: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group) Estrogen therapy, postmenopausal (Vol. 72, Vol. 100A; in preparation) Ethanol [64-17-5] in alcoholic beverages (Vol. 96; in preparation) Ethylene oxide [75-21-8] (Vol. 60, Vol. 97; 2008) (NB: Overall evaluation upgraded from 2A to 1 based on mechanistic and other relevant data) Etoposide [33419-42-0] (Vol. 76, Vol. 100A; in preparation) (NB: Overall evaluation upgraded from 2A to 1 based on mechanistic and other relevant data) Etoposide in combination with cisplatin and bleomycin (Vol. 76, Vol. 100A; in preparation) Formaldehyde [50-00-0] (Vol. 88; 2006) Gallium arsenide [1303-00-0] (Vol. 86; 2006) [Gamma Radiation: see X- and Gamma (g)-Radiation] Helicobacter pylori (infection with) (Vol. 61; 1994) Hepatitis B virus (chronic infection with) (Vol. 59; 1994) Hepatitis C virus (chronic infection with) (Vol. 59; 1994) Human immunodeficiency virus type 1 (infection with) (Vol. 67; 1996) Human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66 (Vol. 64, Vol. 90; 2007) (NB: The HPV types that have been classified as carcinogenic to humans can differ by an order of magnitude in risk for cervical cancer) Human T-cell lymphotropic virus type I (Vol. 67; 1996) Melphalan [148-82-3] (Vol. 9, Suppl. 7, Vol. 100A; in preparation) 8-Methoxypsoralen (Methoxsalen) [298-81-7] plus ultraviolet A radiation (Vol. 24, Suppl. 7, Vol. 100A; in preparation) Methylenebis(chloroaniline) (MOCA) [101-14-4] (Vol. 57, Vol. 99; in preparation) (NB: Overall evaluation upgraded to Group 1 based on mechanistic and other relevant data) MOPP and other combined chemotherapy including alkylating agents (Suppl. 7, Vol. 100A; in preparation) Mustard gas (Sulfur mustard) [505-60-2] (Vol. 9, Suppl. 7; 1987) 2-Naphthylamine [91-59-8] (Vol. 4, Suppl. 7, Vol. 99; in preparation) Neutrons (Vol. 75; 2000) (NB: Overall evaluation upgraded from 2B to 1 with supporting evidence from other relevant data) Nickel compounds (Vol. 49; 1990) N'-Nitrosonornicotine (NNN) [16543-55-8] and 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) [64091-91-4] (Vol. 37, Suppl. 7, Vol. 89; 2007) (NB: Overall evaluation upgraded from 2B to 1 based on mechanistic and other relevant data) [Oestrogen: see Estrogen] Opisthorchis viverrini (infection with) (Vol. 61; 1994) [Oral contraceptives, combined estrogen-progestogen: see Estrogen-progestogen oral contraceptives (combined)] Oral contraceptives, sequential (Suppl. 7, Vol. 100A; in preparation) Phenacetin [62-44-2] (Vol. 24, Suppl. 7, Vol. 100A; in preparation) (NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from other relevant data) Phosphorus-32, as phosphate (Vol. 78; 2001) Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols (Vol. 78; 2001) Radioiodines, short-lived isotopes, including iodine-131, from atomic reactor accidents and nuclear weapons detonation (exposure during childhood) (Vol. 78; 2001) Radionuclides, a-particle-emitting, internally deposited (Vol. 78; 2001) (NB: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents) Radionuclides, b-particle-emitting, internally deposited (Vol. 78; 2001) (NB: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents) Radium-224 and its decay products (Vol. 78; 2001) Radium-226 and its decay products (Vol. 78; 2001) Radium-228 and its decay products (Vol. 78; 2001) Radon-222 [10043-92-2] and its decay products (Vol. 43, Vol. 78; 2001) Schistosoma haematobium (infection with) (Vol. 61; 1994) Silica [14808-60-7], crystalline (inhaled in the form of quartz or cristobalite from occupational sources) (Vol. 68; 1997) Solar radiation (Vol. 55; 1992) Talc containing asbestiform fibres (Vol. 42, Suppl. 7; 1987) Tamoxifen [10540-29-1] (Vol. 66, Vol. 100A; in preparation) (NB: There is also conclusive evidence that tamoxifen reduces the risk of contralateral breast cancer) 2,3,7,8-Tetrachlorodibenzo-para-dioxin [1746-01-6] (Vol. 69; 1997) (NB: Overall evaluation upgraded from 2A to 1 with supporting evidence from other relevant data) Thiotepa [52-24-4] (Vol. 50, Vol. 100A; in preparation) Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium-232 dioxide (Vol. 78; 2001) ortho-Toluidine [95-53-4] (Vol. 77, Vol. 99; in preparation) Treosulfan [299-75-2] (Vol. 26, Suppl. 7, Vol. 100A; in preparation) Vinyl chloride [75-01-4] (Vol. 19, Suppl. 7, Vol. 97; 2008) X- and Gamma (g)-Radiation (Vol. 75; 2000) Mixtures Aflatoxins (naturally occurring mixtures of) [1402-68-2] (Vol. 56, Vol. 82; 2002) Alcoholic beverages (Vol. 44, Vol. 96; in preparation) Areca nut (Vol. 85; 2004) (NB: Overall evaluation based on human data, animal data, and mechanistic and other relevant data) Betel quid with tobacco (Vol. 85; 2004) Betel quid without tobacco (Vol. 85; 2004) Coal-tar pitches [65996-93-2] (Vol. 35, Suppl. 7; 1987) Coal-tars [8007-45-2] (Vol. 35, Suppl. 7; 1987) Household combustion of coal, indoor emissions from (Vol. 95; in preparation) Mineral oils, untreated and mildly treated (Vol. 33, Suppl. 7; 1987) Phenacetin, analgesic mixtures containing (Suppl. 7, Vol. 100A; in preparation) Plants containing aristolochic acid (Vol. 82, Vol. 100A; in preparation) Salted fish (Chinese-style) (Vol. 56; 1993) Shale-oils [68308-34-9] (Vol. 35, Suppl. 7; 1987) Soots (Vol. 35, Suppl. 7; 1987) Tobacco, smokeless (Vol. 37, Suppl. 7, Vol. 89; 2007) Wood dust (Vol. 62; 1995) Group 2A: Probably Carcinogenic to Humans (66) (28 March 2008) Agents and Group of Agents Acrylamide [79-06-1] (Vol. 60; 1994) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Adriamycin [23214-92-8] (Vol. 10, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Androgenic (anabolic) steroids (Suppl. 7; 1987) Aristolochic acids (naturally occurring mixtures of) (Vol. 82; 2002) Azacitidine [320-67-2] (Vol. 50; 1990) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Bischloroethyl nitrosourea (BCNU) [154-93-8] (Vol. 26, Suppl.7; 1987) Captafol [2425-06-1] (Vol. 53; 1991) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Chloramphenicol [56-75-7] (Vol. 50; 1990) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) α-Chlorinated toluenes (benzal chloride [98-87-3], benzotrichloride [98-07-7], benzyl chloride [100-44-7]) and benzoyl chloride [98-88-4] (combined exposures) (Vol. 29, Suppl. 7, Vol. 71; 1999) 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) [13010-47-4](Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) 4-Chloro-ortho-toluidine [95-69-2] (Vol. 77, Vol. 99; in preparation) Chlorozotocin [54749-90-5] (Vol. 50; 1990) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Cisplatin [15663-27-1] (Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Clonorchis sinensis (infection with) (Vol. 61; 1994) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Cyclopenta[cd]pyrene [27208-37-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Dibenz[a,h]anthracene [53-70-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Dibenzo[a,l]pyrene [191-30-0] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Diethyl sulfate [64-67-5] (Vol. 54, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Dimethylcarbamoyl chloride [79-44-7] (Vol. 12, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) 1,2-Dimethylhydrazine [540-73-8] (Vol. 4, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Dimethyl sulfate [77-78-1] (Vol. 4, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Epichlorohydrin [106-89-8] (Vol. 11, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Ethyl carbamate (urethane) [51-79-6] (Vol. 7, Suppl. 7, Vol. 96; in preparation) (NB: Overall evaluation upgraded from 2B to 2A based on mechanistic and other relevant data) Ethylene dibromide [106-93-4] (Vol. 15, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) N-Ethyl-N-nitrosourea [759-73-9] (Vol. 17, Suppl.7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Etoposide [33419-42-0] (Vol. 76; 2000) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Glycidol [556-52-5] (Vol. 77; 2000) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Indium phosphide [22398-80-7] (Vol. 86; 2006) (NB: Overall evaluation upgraded from 2B to 2A) IQ (2-Amino-3-methylimidazo[4,5-f]quinoline) [76180-96-6] (Vol. 56; 1993) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Kaposi's sarcoma herpesvirus/human herpesvirus 8 (Vol. 70; 1997) Lead compounds, inorganic (Vol. 87; 2006) 5-Methoxypsoralen [484-20-8] (Vol. 40, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Methyl methanesulfonate [66-27-3] (Vol. 7, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) N-Methyl-N´-nitro-N-nitrosoguanidine(MNNG) [70-25-7] (Vol. 4, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) N-Methyl-N-nitrosourea [684-93-5] (Vol. 17, Suppl.7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Nitrate or nitrite (ingested) under conditions that result in endogenous nitrosation (Vol. 94; in preparation) Nitrogen mustard [51-75-2] (Vol. 9, Suppl. 7; 1987) N-Nitrosodiethylamine [55-18-5] (Vol. 17, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) N-Nitrosodimethylamine [62-75-9] (Vol. 17, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Phenacetin [62-44-2] (Vol. 24, Suppl. 7; 1987) Procarbazine hydrochloride [366-70-1] (Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Styrene-7,8-oxide [96-09-3] (Vol. 60; 1994) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Teniposide [29767-20-2] (Vol. 76; 2000) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Tetrachloroethylene [127-18-4] (Vol. 63; 1995) Trichloroethylene [79-01-6] (Vol. 63; 1995) 1,2,3-Trichloropropane [96-18-4] (Vol. 63; 1995) Tris(2,3-dibromopropyl) phosphate [126-72-7] (Vol. 20, Suppl. 7, Vol. 71;1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Ultraviolet radiation A (Vol. 55; 1992) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Ultraviolet radiation B (Vol. 55; 1992) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) Ultraviolet radiation C (Vol. 55; 1992) (NB: Overall evaluation upgraded from 2B to 2A with supporting evidence from other relevant data) [Urethane: see Ethyl carbamate] Vinyl bromide [593-60-2] (Vol. 39, Suppl. 7, Vol. 71, Vol. 97; in preparation) (NB: (1) Overall evaluation upgraded from 2B to 2A based on mechanistic and other relevant data; (2) For practical purposes, vinyl bromide should be considered to act similarly to the human carcinogen vinyl chloride.) Vinyl fluoride [75-02-5] (Vol. 63, Vol. 97; in preparation) (NB: (1) Overall evaluation upgraded from 2B to 2A based on mechanistic and other relevant data; (2) For practical purposes, vinyl fluoride should be considered to act similarly to the human carcinogen vinyl chloride.) Mixtures Creosotes [8001-58-9] (Vol. 35, Suppl. 7, Vol. 92; in preparation) Diesel engine exhaust (Vol. 46; 1989) High-temperature frying, emissions from (Vol. 95; in preparation) Hot mate (Vol. 51; 1991) Household combustion of biomass fuel (primarily wood), indoor emissions from (Vol. 95; in preparation) Non-arsenical insecticides (occupational exposures in spraying and application of) (Vol. 53; 1991) Polychlorinated biphenyls [1336-36-3] (Vol. 18, Suppl. 7; 1987) Group 2B: Probably Carcinogenic to Humans (248) (28 March 2008) Agents and Group of Agents A-a-C (2-Amino-9H-pyrido[2,3-b]indole) [26148-68-5] (Vol. 40, Suppl. 7; 1987) Acetaldehyde [75-07-0] (Vol. 36, Suppl. 7, Vol. 71; 1999) Acetamide [60-35-5] (Vol. 7, Suppl. 7, Vol. 71; 1999) Acrylonitrile [107-13-1] (Vol. 71; 1999) AF-2 [2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide] [3688-53-7] (Vol.31, Suppl. 7; 1987) Aflatoxin M1 [6795-23-9] (Vol. 56; 1993) para-Aminoazobenzene [60-09-3] (Vol. 8, Suppl. 7; 1987) ortho-Aminoazotoluene [97-56-3] (Vol. 8, Suppl. 7; 1987) 2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole [712-68-5] (Vol. 7, Suppl. 7; 1987) Amsacrine [51264-14-3] (Vol. 76; 2000) ortho-Anisidine [90-04-0] (Vol. 73; 1999) Antimony trioxide [1309-64-4] (Vol. 47; 1989) Aramite® [140-57-8] (Vol. 5, Suppl. 7; 1987) Auramine [492-80-8] (technical-grade) (Vol. 1, Suppl. 7, Vol. 99; in preparation) Azaserine [115-02-6] (Vol. 10, Suppl. 7; 1987) Aziridine [151-56-4] (Vol. 9, Suppl. 7, Vol. 71; 1999) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Benz[j]aceanthrylene [202-33-5] (Vol. 92; in preparation) (NB: Overall evaluation upgraded from 3 to 2B with supporting mechanistic and other relevant data) Benz[a]anthracene [56-55-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Benzo[b]fluoranthene [205-99-2] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Benzo[j]fluoranthene [205-82-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Benzo[k]fluoranthene [207-08-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Benzofuran [271-89-6] (Vol. 63; 1995) Benzo[c]phenanthrene [195-19-7] (Vol. 32, Suppl. 7, Vol. 92; in preparation) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Benzyl violet 4B [1694-09-3] (Vol. 16, Suppl. 7; 1987) 2,2-Bis(bromomethyl)propane-1,3-diol [3296-90-0] (Vol. 77; 2000) Bleomycins [11056-06-7] (Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Bracken fern (Vol. 40, Suppl. 7; 1987) Bromodichloromethane [75-27-4] (Vol. 52, Vol. 71; 1999) Butylated hydroxyanisole (BHA) [25013-16-5] (Vol. 40, Suppl. 7;1987) b-Butyrolactone [3068-88-0] (Vol. 11, Suppl. 7, Vol. 71; 1999) Caffeic acid [331-39-5] (Vol. 56; 1993) Carbon black [1333-86-4] (Vol. 65, Vol. 93; in preparation) Carbon tetrachloride [56-23-5] (Vol. 20, Suppl. 7, Vol. 71; 1999) Catechol [120-80-9] (Vol. 15, Suppl. 7, Vol. 71; 1999) Chlordane [57-74-9] (Vol. 79; 2001) Chlordecone (Kepone) [143-50-0] (Vol. 20, Suppl. 7; 1987) Chlorendic acid [115-28-6] (Vol. 48; 1990) para-Chloroaniline [106-47-8] (Vol. 57; 1993) 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone [77439-76-0] (Vol. 84; 2004) Chloroform [67-66-3] (Vol. 73; 1999) 1-Chloro-2-methylpropene [513-37-1] (Vol. 63; 1995) [Chlorophenols: see Polychlorophenols] Chlorophenoxy herbicides (Vol. 41, Suppl. 7; 1987) 4-Chloro-ortho-phenylenediamine [95-83-0] (Vol. 27, Suppl.7; 1987) Chloroprene [126-99-8] (Vol. 71; 1999) Chlorothalonil [1897-45-6] (Vol. 73; 1999) Chrysene [218-01-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation) CI Acid Red 114 [6459-94-5] (Vol. 57; 1993) CI Basic Red 9 [569-61-9] (Vol. 57, Vol. 99; in preparation) CI Direct Blue 15 [2429-74-5] (Vol. 57; 1993) Citrus Red No. 2 [6358-53-8] (Vol. 8, Suppl. 7; 1987) Cobalt [7440-48-4] and cobalt compounds (Vol. 52; 1991) (NB: Evaluated as a group) Cobalt sulfate [10026-24-1] and other soluble cobalt(II) salts (Vol. 86; 2006) para-Cresidine [120-71-8] (Vol. 27, Suppl. 7; 1987) Cycasin [14901-08-7] (Vol. 10, Suppl. 7; 1987) Dacarbazine [4342-03-4] (Vol. 26, Suppl. 7; 1987) Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) [117-10-2] (Vol. 50; 1990) Daunomycin [20830-81-3] (Vol. 10, Suppl. 7; 1987) DDT [p,p'-DDT, 50-29-3] (Vol. 53; 1991) N,N'-Diacetylbenzidine [613-35-4] (Vol. 16, Suppl.7; 1987) 2,4-Diaminoanisole [615-05-4] (Vol. 79; 2001) 4,4'-Diaminodiphenyl ether [101-80-4] (Vol. 29, Suppl. 7; 1987) 2,4-Diaminotoluene [95-80-7] (Vol. 16, Suppl. 7; 1987) Dibenz[a,h]acridine [226-36-8] (Vol. 32, Suppl. 7; 1987) Dibenz[a,j]acridine [224-42-0] (Vol. 32, Suppl. 7; 1987) 7H-Dibenzo[c,g]carbazole [194-59-2] (Vol. 32, Suppl.7; 1987) Dibenzo[a,h]pyrene [189-64-0] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Dibenzo[a,i]pyrene [189-55-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation) 1,2-Dibromo-3-chloropropane [96-12-8] (Vol. 20, Suppl. 7, Vol. 71; 1999) 2,3-Dibromopropan-1-ol [96-13-9] (Vol. 77; 2000) Dichloroacetic acid [79-43-6] (Vol. 84; 2004) para-Dichlorobenzene [106-46-7] (Vol. 73; 1999) 3,3'-Dichlorobenzidine [91-94-1] (Vol. 29, Suppl. 7; 1987) 3,3'-Dichloro-4,4'-diaminodiphenyl ether [28434-86-8] (Vol. 16,Suppl. 7; 1987) 1,2-Dichloroethane [107-06-2] (Vol. 20, Suppl. 7, Vol. 71; 1999) Dichloromethane (methylene chloride) [75-09-2] (Vol. 71; 1999) 1,3-Dichloropropene [542-75-6] (technical-grade) (Vol. 41, Suppl.7, Vol. 71; 1999) Dichlorvos [62-73-7] (Vol. 53; 1991) Diepoxybutane [1464-53-5] (Vol. 11, Suppl. 7, Vol. 71, Vol. 97; 2008) 1,2-Diethylhydrazine [1615-80-1] (Vol. 4, Suppl. 7, Vol. 71; 1999) Diglycidyl resorcinol ether [101-90-6] (Vol. 36, Suppl. 7, Vol. 71; 1999) Dihydrosafrole [94-58-6] (Vol. 10, Suppl. 7; 1987) Diisopropyl sulfate [2973-10-6] (Vol. 54, Vol. 71; 1999) 3,3'-Dimethoxybenzidine (ortho-Dianisidine) [119-90-4] (Vol. 4, Suppl. 7; 1987) para-Dimethylaminoazobenzene [60-11-7] (Vol. 8, Suppl. 7; 1987) trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)-vinyl]-1,3,4-oxadiazole [25962-77-0] (Vol. 7, Suppl. 7; 1987) 2,6-Dimethylaniline (2,6-Xylidine) [87-62-7] (Vol. 57; 1993) 3,3'-Dimethylbenzidine (ortho-Tolidine) [119-93-7] (Vol.1, Suppl. 7; 1987) 1,1-Dimethylhydrazine [57-14-7] (Vol. 4, Suppl. 7, Vol. 71; 1999) 3,7-Dinitrofluoranthene [105735-71-5] (Vol. 65; 1996) 3,9-Dinitrofluoranthene [22506-53-2] (Vol. 65; 1996) 1,6-Dinitropyrene [42397-64-8] (Vol. 46; 1989) 1,8-Dinitropyrene [42397-65-9] (Vol. 46; 1989) 2,4-Dinitrotoluene [121-14-2] (Vol. 65; 1996) 2,6-Dinitrotoluene [606-20-2] (Vol. 65; 1996) 1,4-Dioxane [123-91-1] (Vol. 11, Suppl. 7, Vol. 71; 1999) Disperse Blue 1 [2475-45-8] (Vol. 48; 1990) 1,2-Epoxybutane [106-88-7] (Vol. 47, Vol. 71; 1999) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Ethyl acrylate [140-88-5] (Vol. 39, Suppl. 7, Vol. 71; 1999) Ethylbenzene [100-41-4] (Vol. 77; 2000) Ethyl methanesulfonate [62-50-0] (Vol. 7, Suppl. 7; 1987) [Foreign bodies: see Surgical implants and other foreign bodies] 2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole [3570-75-0] (Vol. 7, Suppl. 7; 1987) Fumonisin B1 [116355-83-0] (Vol. 82; 2002) Furan [110-00-9] (Vol. 63; 1995) Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole) [67730-11-4] (Vol. 40, Suppl. 7; 1987) Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole)[67730-10-3] (Vol. 40, Suppl. 7; 1987) Glycidaldehyde [765-34-4] (Vol. 11, Suppl. 7, Vol. 71; 1999) Griseofulvin [126-07-8] (Vol. 79; 2001) HC Blue No. 1 [2784-94-3] (Vol. 57; 1993) Heptachlor [76-44-8] (Vol. 79; 2001) Hexachlorobenzene [118-74-1] (Vol. 79; 2001) Hexachloroethane [67-72-1] (Vol. 73; 1999) Hexachlorocyclohexanes (Vol. 20, Suppl. 7; 1987) Hexamethylphosphoramide [680-31-9] (Vol. 15, Suppl. 7, Vol. 71; 1999) Human immunodeficiency virus type 2 (infection with) (Vol. 67; 1996) Human papillomavirus types 6 and 11 (Vol. 90; 2007) Human papillomavirus genus beta (some types) (Vol. 90; 2007) Hydrazine [302-01-2] (Vol. 4, Suppl. 7, Vol. 71; 1999) 1-Hydroxyanthraquinone [129-43-1] (Vol. 82; 2002) Indeno[1,2,3-cd]pyrene [193-39-5] (Vol. 32, Suppl. 7, Vol. 92; in preparation) Iron-dextran complex [9004-66-4] (Vol. 2, Suppl. 7; 1987) Isoprene [78-79-5] (Vol. 60, Vol. 71; 1999) Lasiocarpine [303-34-4] (Vol. 10, Suppl. 7; 1987) Lead [7439-92-1] (Vol. 23, Suppl. 7; 1987) Magenta (mixtures composed of C.I. Basic Red 9 [569-61-9], methyl fuchsin [632-99-5], dimethyl fuchsin [26261-57-4] or trimethyl fuchsin [3248-91-7]) (Vol. 57, Vol. 99; in preparation) Magnetic fields (extremely low-frequency) (Vol. 80; 2002) MeA-a-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole) [68006-83-7] (Vol. 40, Suppl. 7; 1987) Medroxyprogesterone acetate [71-58-9] (Vol. 21, Suppl. 7; 1987) MeIQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline) [77094-11-2] (Vol. 56; 1993) MeIQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline) [77500-04-0] (Vol. 56; 1993) Merphalan [531-76-0] (Vol. 9, Suppl. 7; 1987) 2-Methylaziridine (Propyleneimine) [75-55-8] (Vol. 9, Suppl. 7, Vol. 71; 1999) Methylazoxymethanol acetate [592-62-1] (Vol. 10, Suppl. 7; 1987) 5-Methylchrysene [3697-24-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation) 4,4'-Methylene bis(2-methylaniline) [838-88-0] (Vol. 4, Suppl.7; 1987) 4,4'-Methylenedianiline [101-77-9] (Vol. 39, Suppl. 7; 1987) Methylmercury compounds (Vol. 58; 1993) (NB: Evaluated as a group) 2-Methyl-1-nitroanthraquinone [129-15-7] (uncertain purity) (Vol.27, Suppl. 7; 1987) N-Methyl-N-nitrosourethane [615-53-2] (Vol. 4, Suppl.7; 1987) Methylthiouracil [56-04-2] (Vol. 79; 2001) Metronidazole [443-48-1] (Vol. 13, Suppl. 7; 1987) Michler's base [4,4'-methylenebis(N,N-dimethyl)benzenamine] [101-61-1] (Vol. 27, Suppl. 7, Vol. 99; in preparation) Michler's ketone [4,4'-bis(dimethylamino)benzophenone] [90-94-8] (Vol. 99; in preparation) Microcystin-LR [101043-37-2] (Vol. 94; in preparation) (NB: Overall evaluation upgraded from 3 to 2B based on mechanistic and other relevant data) Mirex [2385-85-5] (Vol. 20, Suppl. 7; 1987) Mitomycin C [50-07-7] (Vol. 10, Suppl. 7; 1987) Mitoxantrone [65271-80-9] (Vol. 76; 2000) Monocrotaline [315-22-0] (Vol. 10, Suppl. 7; 1987) 5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone [3795-88-8] (Vol. 7, Suppl. 7; 1987) Nafenopin [3771-19-5] (Vol. 24, Suppl. 7; 1987) Naphthalene [91-20-3] (Vol. 82; 2002) Nickel, metallic [7440-02-0] and alloys (Vol. 49; 1990) Niridazole [61-57-4] (Vol. 13, Suppl. 7; 1987) Nitrilotriacetic acid [139-13-9] and its salts (Vol. 73; 1999) (NB: Evaluated as a group) 5-Nitroacenaphthene [602-87-9] (Vol. 16, Suppl. 7; 1987) 2-Nitroanisole [91-23-6] (Vol. 65; 1996) Nitrobenzene [98-95-3] (Vol. 65; 1996) 6-Nitrochrysene [7496-02-8] (Vol. 46; 1989) Nitrofen [1836-75-5] (technical-grade) (Vol. 30, Suppl. 7; 1987) 2-Nitrofluorene [607-57-8] (Vol. 46; 1989) 1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone [555-84-0] (Vol.7, Suppl. 7; 1987) N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide [531-82-8] (Vol. 7, Suppl. 7; 1987) Nitrogen mustard N-oxide [126-85-2] (Vol. 9, Suppl. 7;1987) Nitromethane [75-52-5] (Vol. 77; 2000) 2-Nitropropane [79-46-9] (Vol. 29, Suppl. 7, Vol. 71; 1999) 1-Nitropyrene [5522-43-0] (Vol. 46; 1989) 4-Nitropyrene [57835-92-4] (Vol. 46; 1989) N-Nitrosodi-n-butylamine [924-16-3] (Vol. 17, Suppl.7; 1987) N-Nitrosodiethanolamine [1116-54-7] (Vol. 17, Suppl. 7, Vol. 77; 2000) N-Nitrosodi-n-propylamine [621-64-7] (Vol. 17, Suppl.7; 1987) 3-(N-Nitrosomethylamino)propionitrile [60153-49-3] (Vol. 85; 2004) N-Nitrosomethylethylamine [10595-95-6] (Vol. 17, Suppl. 7; 1987) N-Nitrosomethylvinylamine [4549-40-0] (Vol. 17, Suppl. 7; 1987) N-Nitrosomorpholine [59-89-2] (Vol. 17, Suppl. 7; 1987) N-Nitrosopiperidine [100-75-4] (Vol. 17, Suppl. 7; 1987) N-Nitrosopyrrolidine [930-55-2] (Vol. 17, Suppl. 7; 1987) N-Nitrososarcosine [13256-22-9] (Vol. 17, Suppl. 7; 1987) Ochratoxin A [303-47-9] (Vol. 56; 1993) Oil Orange SS [2646-17-5] (Vol. 8, Suppl. 7; 1987) Oxazepam [604-75-1] (Vol. 66; 1996) Palygorskite (attapulgite) [12174-11-7] (long fibres, > 5 micrometres) (Vol. 68; 1997) Panfuran S [794-93-4] (containing dihydroxymethylfuratrizine) (Vol. 24, Suppl. 7; 1987) Phenazopyridine hydrochloride [136-40-3] (Vol. 24, Suppl. 7; 1987) Phenobarbital [50-06-6] (Vol. 79; 2001) Phenolphthalein [77-09-8] (Vol. 76; 2000) Phenoxybenzamine hydrochloride [63-92-3] (Vol. 24, Suppl. 7; 1987) Phenyl glycidyl ether [122-60-1] (Vol. 47, Vol. 71; 1999) Phenytoin [57-41-0] (Vol. 66; 1996) PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) [105650-23-5] (Vol. 56; 1993) Polychlorophenols and their sodium salts (mixed exposures) (Vol. 41, Suppl. 7, Vol. 53, Vol. 71; 1999) Ponceau MX [3761-53-3] (Vol. 8, Suppl. 7; 1987) Ponceau 3R [3564-09-8] (Vol. 8, Suppl. 7; 1987) Potassium bromate [7758-01-2] (Vol. 73; 1999) Progestins (Suppl. 7; 1987) Progestogen-only contraceptives (Vol. 72; 1999) 1,3-Propane sultone [1120-71-4] (Vol. 4, Suppl. 7, Vol. 71; 1999) b-Propiolactone [57-57-8] (Vol. 4, Suppl. 7, Vol. 71; 1999) Propylene oxide [75-56-9] (Vol. 60; 1994) Propylthiouracil [51-52-5] (Vol. 79; 2001) Refractory ceramic fibres (Vol. 43, Vol. 81; 2002) Riddelliine [23246-96-0] (Vol. 10, Suppl. 7, Vol. 82; 2002) Safrole [94-59-7] (Vol. 10, Suppl. 7; 1987) Schistosoma japonicum (infection with) (Vol. 61; 1994) Sodium ortho-phenylphenate [132-27-4] (Vol. 73; 1999) Special-purpose fibres such as E-glass and '475' glass fibres (Vol. 81; 2002) Sterigmatocystin [10048-13-2] (Vol. 10, Suppl. 7; 1987) Streptozotocin [18883-66-4] (Vol. 17, Suppl. 7; 1987) Styrene [100-42-5] (Vol. 60, 82; 2002) Sulfallate [95-06-7] (Vol. 30, Suppl. 7; 1987) Surgical implants and other foreign bodies (Vol. 74; 1999): - Polymeric implants prepared as thin smooth film (with the exception of poly(glycolic acid)) - Metallic implants prepared as thin smooth films - Implanted foreign bodies of metallic cobalt, metallic nickel and an alloy powder containing 66-67% nickel, 13-16% chromium and 7% iron Tetrafluoroethylene [116-14-3] (Vol. 19, Suppl. 7, Vol. 71; 1999) Tetranitromethane [509-14-8] (Vol. 65; 1996) Thioacetamide [62-55-5] (Vol. 7, Suppl. 7; 1987) 4,4'-Thiodianiline [139-65-1] (Vol. 27, Suppl. 7; 1987) Titanium dioxide [13463-67-7] (Vol. 47, Vol. 93; in preparation) Thiouracil [141-90-2] (Vol. 79; 2001) Toluene diisocyanates [26471-62-5] (Vol. 39, Suppl. 7, Vol. 71; 1999) Trichlormethine (Trimustine hydrochloride) [817-09-4] (Vol. 50; 1990) Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole)[62450-06-0] (Vol. 31, Suppl. 7; 1987) Trp-P-2 (3-Amino-1-methyl-5H-pyrido[4,3-b]indole)[62450-07-1] (Vol. 31, Suppl. 7; 1987) Trypan blue [72-57-1] (Vol. 8, Suppl. 7; 1987) Uracil mustard [66-75-1] (Vol. 9, Suppl. 7; 1987) Vanadium pentoxide [1314-62-1] (Vol. 86; 2006) Vinyl acetate [108-05-4] (Vol. 63; 1995) 4-Vinylcyclohexene [100-40-3] (Vol. 60; 1994) 4-Vinylcyclohexene diepoxide [106-87-6] (Vol. 60; 1994) Zalcitabine [7481-89-2] (Vol. 76; 2000) Zidovudine (AZT) [30516-87-1] (Vol. 76; 2000) Mixtures Bitumens [8052-42-4], extracts of steam-refined and air-refined (Vol. 35, Suppl. 7; 1987) Carrageenan [9000-07-1], degraded (Vol. 31, Suppl. 7; 1987) Chlorinated paraffins of average carbon chain length C12 and average degree of chlorination approximately 60% (Vol. 48; 1990) Coffee (urinary bladder) (Vol. 51; 1991) (NB: There is some evidence of an inverse relationship between coffee drinking and cancer of the large bowel; coffee drinking could not be classified as to its carcinogenicity to other organs) Diesel fuel, marine (Vol. 45; 1989) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Engine exhaust, gasoline (Vol. 46; 1989) Fuel oils, residual (heavy) (Vol. 45; 1989) Gasoline (Vol. 45; 1989) (NB: Overall evaluation upgraded from 3 to 2B with supporting evidence from other relevant data) Pickled vegetables (traditional in Asia) (Vol. 56; 1993) Polybrominated biphenyls [Firemaster BP-6, 59536-65-1] (Vol. 41, Suppl. 7; 1987) Toxaphene (Polychlorinated camphenes) [8001-35-2] (Vol. 79; 2001) Toxins derived from Fusarium moniliforme: fumonisin B1 and B2 and fusarin C (Vol. 56; 1993) Welding fumes (Vol. 49; 1990)

Source: http://sweet.ua.pt/filipe.paz/CICECO/images/Lists.pdf